Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 490

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 4
Chunk 490
---
 each non-employee director
was granted an additional option to purchase up to 25,000 shares of our common stock under the 2022 Omnibus Plan. Each such option vested
in terms ranging from immediate vesting to one year following the grant. Each grant has a 10-year term.

Item
11. Executive Compensation

This
section discusses the material components of the executive compensation program for the following persons: (i) all persons serving as
our principal executive officers during 2024 and (ii) the most highly compensated of our other executive officers who received compensation
during 2024 of at least $100,000 and who were executive officers on December 31, 2024. We refer to these persons as our “named
executive officers” elsewhere in this Report. Our “named executive officers” and their positions are as follows:

    ●
    Erez
    Aminov, Chief Executive Officer and Chairman;

    ●
    Michelle
    Yanez, MBA, Chief Financial Officer, Secretary and Treasurer. 

71

Summary
Compensation Table

The
following table shows the compensation paid by us during the 2024 and 2023 fiscal years to our named executive officers.

    Name
    and principal position 
    Year  
    Salary
    ($)  
    Bonus
    ($)  
    Stock
    Awards ($)  
    Option
    Awards ($) (6)  
    Non-Equity
    Incentive Plan Compensation ($)  
    Nonqualified
                                            Deferred Compensation Earnings ($)  
    All
    Other Compensation ($)  
    Total ($) 
  
    Erez
    Aminov, 
    2024  
     259,999  
     300,000  (1) 
     595,000 (2) 
     1,919,120  
           -  
           -  
     66,194 (3) 
     3,140,313 
  
    CEO 
    2023  
     83,333  
     208,006 (4) 
     -  
     1,368,600  
     -  
     -  
     5,625 (5) 
     1,665,564 

    Michelle
    Yanez, 
    2024  
     158,219